Top 15 Chinese Pharma Companies by Innovative Drug Revenue in H1 2025

Every dayShitInnovative DrugEarn1 IndividualSmall Goals！A Few YearsFront，In ChinaPharmaceutical companyPossibleThink AllDare notThink，ButNowHoweverBecomeCompletedReality. This yearFirst Half of the Year，In ChinaPharmaceutical companyByInnovative DrugUltimatelyEarnedHow much？Let's take a look together.

BeOne Medicines' total revenue in the first half of the year17.5 billion yuan(Including product sales revenue, collaboration licensing revenue), being the best performer among all pharmaceutical companies. This is mainly attributed to Brukinsa.(Zanubrutinib)And BeOne Medicines(Tislelizumab)Two products. Especially Brukinsa, as the global BIC, sold directly in the first half of the year.12.5 billion yuan！

Hengrui Pharma ranked second, with a total revenue ofRMB 9.56 billion, including7.5 billion yuan in innovative product sales revenue, and 2 billion yuan inBD Initial Payment(From Merck, IDEAYA). More importantly, in the first half of this year, the proportion of its innovative drug revenue exceeded 50% for the first time.（60.66%）, successfully achieved innovative transformation at the financial level，Congratulations and Celebrations。

The third is Sino Biopharm, with innovative drug revenue in the first half of the year.Surge by 28%, reaching 7.8 billion yuan, and the proportion of total revenue has increased from 30% in previous years to 44%In July this year, it also acquired Lexing through acquisition, gaining access to bispecific antibody and ADC technology platforms, along with a series of assets.FIC/BIC PotentialProducts that are expected to become new growth points in the future.

Hansoh and Innovent rank fourth and fifth, respectively. The innovative drug revenues of these two companies are very close.(6.145 billion yuan vs. 5.953 billion yuan), with a difference of less than 200 million.

However, Innovent Bio's growth rate is truly impressive.Ah,足足有 51%, coupled with its highly imaginative market potentialXinerBeauty(Mashidu Peptide)It has been listed, and in the future, it may break into the top three.

In addition, Fosun,Yofoto、Legends, Simcere, Allist Pharmaceuticals, Betta Pharmaceuticals, Zai Lab... These pharmaceutical companies have also made it into the TOP 15 list.. Among themLegend and Allist Pharmaceuticals, thanks to a single blockbuster product.Cilta-cel Sales Reach 5.8 Billion in the First Half of the Year($808 million), dividedLegend3 Billion. Furmonertinib sales reached 23.6 billion yuan in the first half of the year, propping up Allist Pharmaceuticals.EntirePerformance.

Source: Insight Compilation

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb